Epidemic waves and cytokine signatures of seven respiratory pathogens after COVID-19 restrictions
Background: Non-pharmaceutical interventions (NPIs) during COVID-19 created population-level immunity debt. Following NPI lifting in China (May 2023), clinicians face unprecedented resurgence patterns of respiratory pathogens with altered age distributions and co-infection dynamics, but comprehensive comparative cytokine profiling across diverse pathogens remains limited. Methods: We conducted a 20-month prospective-retrospective surveillance study (June 2024-January 2026) of 54,902 febrile patients, with nested cytokine profiling (n=187) across 11 groups using a 47-analyte multiplex panel. Random forest machine learning with 10-fold stratified cross-validation identified optimal cytokine panels for pathogen discrimination. Results: Three sequential epidemic waves emerged: Wave 1 (July-August 2024, SARS-CoV-2, n=1,988), Wave 2 (December 2024-March 2025, IAV, n=5,373), and Wave 3 (November 2025-January 2026, IAV+HRV, n=8,567). The 9.5% co-infection rate (2,986 cases) fell within the upper pre-pandemic range. G-CSF and IL-1Ra were universally elevated across all pathogens (1.4- to 100.2-fold and 1.8- to 41.7-fold vs. healthy controls, respectively), serving as broad inflammatory markers. Machine learning classification using five cytokines (MIF, IP-10, RANTES, G-CSF, IL-1Ra) achieved 87.3% cross-validated accuracy (95% CI 82.1-92.4%) for pathogen-group discrimination. IAV exhibited a unique IL-4-dominant profile (105.8-fold elevation, η²=0.84), while MP demonstrated distinct immune suppression (IL-16 and PDGF-BB suppressed 0.5-fold). Co-infections generated supra-additive cytokine amplification (e.g., MIG 36.6-fold in HRV+MP vs. 4.2- to 7.3-fold in single infections) and dysregulated IL-10 anti-inflammatory feedback. Conclusions: Pathogen-specific cytokine signatures enable rapid etiological inference from single plasma samples. G-CSF and IL-1Ra serve as universal ARI screening markers, while IAV-specific IL-4 elevation and MP-specific immune suppression offer diagnostic and therapeutic targets for precision medicine in respiratory infectious diseases.
Authors
- Jianfeng Zhong (ORCID: https://orcid.org/0000-0003-0863-0501)
- Meiling Xu (ORCID: https://orcid.org/0009-0002-6391-1015)
- Kefeng Qin (ORCID: https://orcid.org/0009-0006-9570-1425)
- Lili Zhao (ORCID: https://orcid.org/0009-0002-2398-0219)
- Yong Tong
- Zhaowei Tong
- Jiawei Zhu
- Zhengyi Bao
- Qun Gao
- Tingting Bian
Institutions
- Huzhou Central Hospital (CN)
Publication Details
- Journal
- iScience
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1016/j.isci.2026.118204
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00